The End of an Era, Coonoor Polio Vaccine Unit to Close After Decades of Service
As India’s Polio-Free Status Transforms the Landscape of Public Health, a Once-Critical Production Facility Faces Its Final Chapter
New Delhi, March 17: The oral polio vaccine production unit at the Pasteur Institute, Coonoor, will be closed with effect from March 31. The decision marks the end of a facility that has played a significant role in India’s public health history, producing vaccines that helped protect millions of children from a disease that once paralyzed tens of thousands every year.
Meanwhile, there is a move for handing over the institute itself to the Centre, signaling a broader restructuring of how vaccine production and public health infrastructure are managed in the country.
The closure of the vaccine unit, run with Central grants routed through the Indian Council of Medical Research, was decided upon by the Health Ministry on the basis of the opinion of technical experts who had gone into its defective functioning. The technical opinion was that the unit could not be revived without a very heavy expenditure and that even then it was doubtful whether it would be able to produce good, acceptable and safe vaccine.
This is not merely a story about a single facility closing its doors. It is a story about how public health priorities shift, how infrastructure ages, and how the successes of the past create new challenges for the present. It is also a story about governance, accountability, and the difficult choices that must be made when facilities outlive their usefulness.
The History of the Pasteur Institute, Coonoor
The Pasteur Institute in Coonoor, nestled in the Nilgiri hills of Tamil Nadu, has a long and storied history. Established in the early 20th century, it was part of a network of institutes named after the French scientist Louis Pasteur, dedicated to the study and prevention of infectious diseases. For decades, it produced vaccines that were essential to India’s public health efforts.
The oral polio vaccine production unit was established at the institute to support India’s fight against polio. At its peak, polio was one of the most feared diseases in the country, paralyzing thousands of children every year. The vaccine produced at Coonoor was part of the national effort to eradicate the disease—an effort that ultimately succeeded.
In 2014, India was declared polio-free by the World Health Organization. It was a monumental achievement, the result of decades of sustained effort, mass vaccination campaigns, and the dedication of health workers across the country. The Coonoor facility played its part in that success.
But success brought new challenges. With polio eliminated, the demand for oral polio vaccine dropped dramatically. Facilities that had been built to produce millions of doses were no longer needed at the same scale. The infrastructure that had served the nation well began to age, and questions arose about its future.
The Technical Assessment
The decision to close the vaccine unit was based on the opinion of technical experts who had gone into its defective functioning. The technical opinion was stark: the unit could not be revived without a very heavy expenditure, and even then it was doubtful whether it would be able to produce good, acceptable and safe vaccine.
This assessment is not a reflection of past failures but of present realities. Vaccine production is a highly complex, highly regulated activity. It requires state-of-the-art facilities, rigorous quality control, and continuous investment. Facilities that were adequate decades ago may no longer meet current standards. Equipment ages. Processes become outdated. The cost of bringing a facility up to modern standards can be prohibitive.
The experts concluded that the Coonoor unit had reached that point. The investment required to revive it would be substantial, and the outcome uncertain. In a context where polio vaccine is now produced in more modern facilities elsewhere, and where global demand has declined, the case for closure became overwhelming.
The Problem of Dual Control
One of the factors found to have affected the functioning of the unit was dual control. Although the unit was functioning in the Institute, it was an ICMR project, and as such there had been a lack of rapport between the unit staff and the Institute Director.
This is a recurring problem in India’s public health infrastructure. When responsibilities are divided between different agencies, when lines of authority are unclear, when coordination is weak, the result is often inefficiency and dysfunction. The Public Accounts Committee of the Lok Sabha had also commented on this sorry state of affairs.
The dual control issue at Coonoor was not unique. It is a symptom of a broader challenge in how public health institutions are governed. The closure of the vaccine unit may be an opportunity to rethink these governance structures, to create clearer lines of authority, and to ensure that future investments are made in facilities that can be effectively managed.
The Move to Centralise
A suggestion was made at one stage that the Institute managed by an Association be handed over to the Centre to ensure effective functioning of the Institute and the vaccine unit. Now, with the vaccine unit closing, the move to hand over the institute itself to the Centre appears to be moving forward.
Centralisation has its advantages. It can bring clarity of purpose, unified command, and economies of scale. It can ensure that facilities are managed according to consistent standards. But it also carries risks: distance from local needs, bureaucratic inertia, and the loss of institutional memory and expertise.
The fate of the Pasteur Institute, Coonoor, will depend on how it is managed under its new structure. If it is given a clear mission, adequate resources, and the autonomy to pursue its goals, it could continue to serve the nation in new ways. If it is absorbed into a larger bureaucracy without a clear purpose, it may decline further.
The Broader Context
The closure of the Coonoor polio vaccine unit is part of a larger transformation in India’s public health landscape. The success of the polio eradication campaign has freed up resources and attention for other priorities. New vaccines are being introduced, new diseases are being targeted, and new challenges are emerging.
At the same time, India is investing in strengthening its vaccine production capacity. The COVID-19 pandemic demonstrated the importance of having domestic manufacturing capabilities for critical health products. The government has been supporting the development of new facilities, new technologies, and new partnerships with the private sector.
In this context, the closure of an ageing facility like Coonoor is not a sign of decline but of transition. It is a recognition that resources are finite and that they must be deployed where they can have the greatest impact. It is a decision to invest in the future rather than to prop up the past.
The Human Dimension
Behind the policy decisions and technical assessments are real people. The staff of the vaccine unit, many of whom have worked there for years, will lose their jobs. The local community, which has been connected to the institute for generations, will feel the loss. The closure represents an end to a way of life.
The government must manage this transition humanely. Workers should be offered alternative employment opportunities, retraining, or fair compensation. The community should be engaged in discussions about the institute’s future. The closure should not be allowed to become a source of bitterness or resentment.
The Future of the Institute
The Pasteur Institute, Coonoor, will not disappear. It will be handed over to the Centre, and its future will be determined by new leadership and new priorities. What could it become?
One possibility is that it could be repurposed as a centre for research on diseases that are still prevalent in the region—perhaps tuberculosis, which remains a major public health challenge in India. Another possibility is that it could become a training facility for public health workers, building on its long history of service. Yet another is that it could be integrated into a larger network of vaccine research and production facilities, focusing on new vaccines for emerging diseases.
Whatever path is chosen, it should be guided by a clear vision and a commitment to excellence. The institute’s history deserves to be honoured, but it should not be allowed to become a museum. It should be given a new mission that builds on its strengths and serves the nation’s needs.
Conclusion: A Chapter Closes
The closure of the oral polio vaccine production unit at the Pasteur Institute, Coonoor, marks the end of a chapter in India’s public health history. For decades, this facility produced vaccines that protected millions of children from a devastating disease. Its work was part of a national effort that ultimately succeeded in eliminating polio from the country.
But success brings change. The needs of today are not the needs of yesterday. The facilities that served us well in the past may not be adequate for the future. The closure of the Coonoor unit is a recognition of this reality.
The challenge now is to manage the transition well: to honour the past, to support those affected, and to create a new future for the institute. The Pasteur Institute, Coonoor, has served the nation for over a century. With the right vision and the right leadership, it can continue to serve for another century.
Q&A: Unpacking the Coonoor Polio Vaccine Unit Closure
Q1: Why is the oral polio vaccine production unit at Coonoor being closed?
A: The Health Ministry decided to close the unit based on technical expert opinion that the facility could not be revived without very heavy expenditure, and that even then it was doubtful whether it could produce good, acceptable, and safe vaccine. The unit had been experiencing defective functioning, and the cost of bringing it up to modern standards was deemed prohibitive. The closure takes effect from March 31.
Q2: What role did the Coonoor unit play in India’s public health history?
A: The unit was part of the national effort to eradicate polio, producing oral polio vaccine that helped protect millions of children. In 2014, India was declared polio-free by the World Health Organization—a monumental achievement that the Coonoor facility contributed to. With polio eliminated, demand for the vaccine dropped dramatically, and the ageing facility faced questions about its future viability.
Q3: What governance problems affected the unit’s functioning?
A: The unit suffered from dual control. Although it functioned within the Pasteur Institute, it was an ICMR project. This led to a lack of rapport between the unit staff and the Institute Director. The Public Accounts Committee of the Lok Sabha had previously commented on this situation. The problem of divided authority and unclear lines of accountability contributed to the unit’s dysfunction.
Q4: What is the future of the Pasteur Institute itself?
A: There is a move to hand over the Institute, currently managed by an Association, to the Centre. With the vaccine unit closing, this centralisation may proceed. The Institute’s future will depend on how it is managed under new structures—whether it is given a clear mission and adequate resources, or absorbed into bureaucracy without purpose. Possibilities include repurposing it as a research centre, training facility, or part of a larger vaccine production network.
Q5: What broader lessons does this closure offer?
A: The closure illustrates several broader lessons: public health priorities shift over time, and infrastructure must adapt; facilities that were adequate decades ago may no longer meet current standards; governance structures with unclear authority lead to dysfunction; and successful public health campaigns create new challenges of managing legacy infrastructure. It also highlights the need for humane transition planning for affected workers and communities, and the importance of reinvesting resources where they can have the greatest impact.
